UNIVERSITY OF MIAMI

UCLA and UC Davis will co-lead the PRISM Trial, a $16 million randomized controlled study evaluating artificial intelligence support for mammogram interpretation across seven academic medical centers.

The HDAC inhibitors market across seven major markets is expected to surge significantly by 2034, driven by innovation in cancer therapies and expanding applications beyond traditional hematologic malignancies.

Longeveron has licensed US Patent 12,168,028 B2 from the University of Miami, protecting unique GHRH-Receptor+ cardiomyogenic cells derived from induced pluripotent stem cells.

The BIRD Foundation approved a fifth milestone payment of approximately $166,000 USD to support continued development of iTOL-102, a potential cure for Type 1 diabetes that would eliminate the need for lifelong immunosuppression.

Florida becomes the first state to offer comprehensive newborn genetic screening through the Sunshine Genetics Pilot Program, providing free genetic sequencing to identify serious but treatable conditions before symptoms appear.

The FDA has authorized emergency compassionate use of ZyVersa Therapeutics' VAR 200 for a patient with ApoCII amyloidosis, an ultra-rare kidney disease with no effective treatment options.

Adolore BioTherapeutics published preclinical data in Molecular Therapy demonstrating biosafety and efficacy of its rdHSV-CA8* gene therapy for chronic knee pain from osteoarthritis.

The phase 2/3 Alliance A092104 trial evaluating olaparib plus temozolomide in advanced uterine leiomyosarcoma failed to meet its primary progression-free survival endpoint compared to standard care.

The FDA's Oncology Drugs Advisory Committee unanimously approved minimal residual disease (MRD) as an end point for accelerated approval of multiple myeloma therapies in April 2024, potentially reducing trial timelines from 10-15 years to just 3 years.

Alcohol-related deaths in the United States nearly doubled from 1999 to 2020, rising from 10.7 to 21.6 per 100,000 people, with women experiencing the largest relative increase despite men having higher overall rates.